

FEB 05 2003

Sheet 1 Of 1

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	A-748E	09/685.053
	Applicant	
	Armistead et al.	
	Filing Date	Group
	October 6, 2000	1624

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1					
	A2					
	A3					
	A4					
	A5					

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
					YES NO
B1					
B2					
B3					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

VB	C2	Arteaga et al. "HER (erbB) Tyrosine Kinase Inhibitors in the Treatment of Breast Cancer" Seminars in Oncology 29(No. 2 Suppl. 11) 4-10 (2002).
VB	C3	Bolen et al., "Leukocyte Protein Tyrosine Kinases: Potential Targets for Drug Discovery" Annu. Rev. Immunology 15: 371-404 (1997)
M	C4	Cao et al., "Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models" PNAS (Proceedings of the National Academy of Sciences of the United States of America) 98:13 7443-7448.
h	C5	Khandwala et al. "The effects of Insulin-like growth factors on Tumorigenesis and Neoplastic Growth" Endocrine Reviews 21(3): 215-244 (2000)
VB	C6	Muller et al., "Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia" Leukemia Research 26:163-168 (2002)
M	C7	Raymond et al., "Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy" Drugs 60 Suppl.1: 15-23 (2000)
VB	C8	Scheijen et al. "Tyrosine kinase oncogenes in normal hematopoiesis and hemtological disease" Oncogene 21: 3314-3333 (2002)
VB	C9	Sweeney et al., "Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor" Kidney International, 57: 33-40 (2000)

EXAMINER:

V. Balasubraman

Date Considered:

4/28/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.